Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV

AIDS

Volumn 30, Issue 1, 2016, Pages 65-73

  Hileman, Corrilynn O ^a,b   Turner, Randi ^c   Funderburg, Nicholas T ^d   Semba, Richard D ^c   McComsey, Grace A ^b,e  

^a MetroHealth Medical Center   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

human immunodeficiency virus; inflammation; oxidative stress; oxidized low density lipoprotein; rosuvastatin

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; DARUNAVIR; DIDANOSINE; EMTRICITABINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MARAVIROC; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; RNA; ROSUVASTATIN; TENOFOVIR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; CREATININE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN;

ADULT; ANALYTICAL PARAMETERS; ANTIVIRAL THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; CELL ACTIVATION; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; F2 ISOPROSTANE CREATININE RATIO; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; VASCULAR DISEASE; AGED; BLOOD; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VASCULAR DISEASES;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CAROTID INTIMA-MEDIA THICKNESS; CREATININE; F2-ISOPROSTANES; FEMALE; HIV INFECTIONS; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MONOCYTES; PLACEBOS; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 84957613332     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000885     Document Type: Article

References (61)

1. Paisible AL, Chang CC, So-Armah KA, Butt AA, Leaf DA, Budoff M, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr 2015; 68:209-216.
2. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-622.
3. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512.
4. Rasmussen LD, Helleberg M, May MT, Afzal S, Kronborg G, Larsen CS, et al. Myocardial infarction among Danish HIVinfected individuals: population-attributable fractions associated with smoking. Clin Infect Dis 2015; 60:1415-1423.
5. Stein JH, Brown TT, Ribaudo HJ, Chen Y, Yan M, Lauer-Brodell E, et al. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS 2013; 27:929-937.
6. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
7. Hileman CO, Longenecker CT, Carman TL, McComsey GA. C-reactive protein predicts 96-week carotid intima media thickness progression in HIV-infected adults naive to antiretroviral therapy. J Acquir Immune Defic Syndr 2014; 65:340-344.
8. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-1127.
9. Baker JV, Hullsiek KH, Singh A, Wilson E, Henry K, Lichtenstein K, et al. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS 2014; 28:831-840.
10. McKibben RA, Margolick JB, Grinspoon S, Li X, Palella FJ Jr, Kingsley LA, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis 2015; 211:1219-1228.
11. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-386.
12. Li H, Horke S, Forstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 2014; 237:208-219.
13. Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol 2012; 60:2218-2229.
14. Gomez M, Vila J, Elosua R, Molina L, Bruguera J, Sala J, et al. Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population. Atherosclerosis 2014; 232:134-140.
15. Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, Cenic-Milosevic D, et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci 2015; 52:70-85.
16. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J Cardiol 2006; 113:167-173.
17. Duong M, Petit JM, Martha B, Galland F, Piroth L, Walldner A, et al. Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. HIV Clin Trials 2006; 7:41-47.
18. Parra S, Coll B, Aragones G, Marsillach J, Beltran R, Rull A, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med 2010; 11:225-231.
19. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.NEngl J Med 2008; 359:2195-2207.
20. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014; 209:1156-1164.
21. Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr 2015; 68:396-404.
22. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in hiv-infected subjects on antiretroviral therapy. Clin Infect Dis 2014; 58:588-595.
23. Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: The SATURNHIV trial. Clin Infect Dis 2014; 59:1148-1156.
24. Profumo E, Buttari B, Saso L, Rigano R. Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin. Curr Top Med Chem 2014; 14:2542-2551.
25. Mihos CG, Pineda AM, Santana O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res 2014; 88:12-19.
26. Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol 2014; 10:140-147.
27. Aydin MU, Aygul N, Altunkeser BB, Unlu A, Taner A. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction. Atherosclerosis 2015; 239:439-443.
28. Molcanyiova A, Stancakova A, Javorsky M, Tkac I. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia. Pharmacol Res 2006; 54:203-207.
29. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effects of atorvastatin on oxidative stress in chronic kidney disease. Nephrology (Carlton) 2015[Epub ahead of print].
30. Tsikas D, Pham VV, Suchy MT, van de Ree MA, Huisman MV, Frolich JC, et al. No effects of atorvastatin (10 mg/d or 80 mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. Pharmacol Res 2015; 94:1-8.
31. Longenecker CT, Jiang Y, Debanne SM, Labbato D, Kinley B, Storer N, et al. Rosuvastatin arrests progression of carotid intima-media thickness in Treated HIV. Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 2015.
32. Stein JH, Korcarz C E, Hurst R T, Lonn E, Kendall C B, Mohler E R, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21:93-111quiz 189-190.
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
34. Zidar DA, Juchnowski S, Ferrari B, Clagett B, Pilch-Cooper HA, Rose S, et al. Oxidized LDL levels are increased in hiv infection and may drive monocyte activation. J Acquir Immune Defic Syndr 2015; 69:154-160.
35. Itabe H, Suzuki K, Tsukamoto Y, Komatsu R, Ueda M, Mori M, et al. Lysosomal accumulation of oxidized phosphatidylcholine-apolipoprotein B complex in macrophages: intracellular fate of oxidized low density lipoprotein. Biochim Biophys Acta 2000; 1487:233-245.
36. Itabe H, Takano T. Oxidized low density lipoprotein: The occurrence and metabolism in circulation and in foam cells. J Atheroscler Thromb 2000; 7:123-131.
37. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, et al. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995; 96:2322-2330.
38. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol 2002; 40:611-617.
39. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 1165:335-338.
40. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Antioxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154:87-96.
41. Yasuhara M, Suzumura K, Tanaka K, Takahashi M, Aoki S, Odawara A, et al. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. Biol Pharm Bull 2000; 23:570-574.
42. Mirjanic-Azaric B, Rizzo M, Jurgens G, Hallstroem S, Srdic S, Marc J, et al. Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients. Scand J Clin Lab Invest 2015; 75:382-389.
43. Bostan C, Yildiz A, Ozkan AA, Uzunhasan I, Kaya A, Yigit Z. Beneficial effects of rosuvastatin treatment in patients with metabolic syndrome. Angiology 2015; 66:122-127.
44. Tsai NW, Lee LH, Huang CR, Chang WN, Chang YT, Su YJ, et al. Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome. Crit Care 2014; 18:R16.
45. Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis 2013; 231:8-14.
46. Akalin A, Temiz G, Akcar N, Sensoy B. Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes. Endocr J 2008; 55:861-866.
47. Tavridou A, Efthimiadis A, Efthimiadis I, Manolopoulos VG. Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia. Heart Vessels 2010; 25:288-293.
48. Azar RR, Badaoui G, Sarkis A, Azar M, Aydanian H, Harb S, et al. Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. Am J Cardiol 2010; 106:193-197.
49. Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study. Atherosclerosis 2010; 210:194-198.
50. Huang B, Cheng Y, Xie Q, Lin G, Wu Y, Feng Y, et al. Effect of 40mg versus 10mg of atorvastatin on oxidized low-density lipoprotein, high-sensitivity C-reactive protein, circulating endothelial-derived microparticles, and endothelial progenitor cells in patients with ischemic cardiomyopathy. Clin Cardiol 2012; 35:125-130.
51. Kougialis S, Skopelitis E, Gialernios T, Nikolaou S, Kroustalis A, Katsadorou E, et al. Atorvastatin therapy is associated with improvement of oxidized low-density lipoprotein cholesterol levels, which correlates with the degree of stenosis in patients with carotid atheromatosis with and without prior angioplasty. Int Angiol 2010; 29:338-347.
52. Homma Y, Michishita I, Hayashi H, Shigematsu H. Effects of low-dose simvastatin on the distribution of plasma cholesterol and oxidized low-density lipoprotein in three ultra-centrifugally separated low-density lipoprotein subfractions: 12-month, open-label trial. J Atheroscler Thromb 2010; 17:1049-1053.
53. Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010; 209:178-183.
54. Ajeganova S, de Faire U, Jogestrand T, Frostegard J, Hafstrom I. Carotid atherosclerosis, disease measures, oxidized lowdensity lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis-an inception cohort study. J Rheumatol 2012; 39:1146-1154.
55. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005; 10 (Suppl 1):S10-23.
56. Morrow JD, Minton TA, Roberts LJ 2nd. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/ endoperoxide receptor antagonist. Prostaglandins 1992; 44:155-163.
57. Minuz P, Andrioli G, Degan M, Gaino S, Ortolani R, Tommasoli R, et al. The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 1998; 18:1248-1256.
58. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28:505-513.
59. Montuschi P, Barnes P, Roberts LJ 2nd. Insights into oxidative stress: The isoprostanes. Curr Med Chem 2007; 14:703-717.
60. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008; 51:1653-1662.
61. Hewitt CE, Kumaravel B, Dumville JC, Torgerson DJ. Assessing the impact of attrition in randomized controlled trials. J Clin Epidemiol 2010; 63:1264-1270.